TrialJournal of Alzheimer's disease : JAD2024

Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).

Anuja Neve et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.